Membri:Antonio Amoroso (Dip. Scienze Mediche)
Struttura Complessa di Gastroenterologia ed Epatologia - Ospedale Infantile Regina Margherita - S.Anna di Torino, Italy
Medical Science, University of Turin, Italy (verificare nuovo link)
Surgical Science, University of Turin, Italy (verificare nuovo link)
University of Turin (ex 60%)
The immunosuppressive drugs used in solid organ transplantation are potent and toxic drugs with narrow therapeutic range. Underdosing is associated with immunological rejection of the transplanted organ, whereas overdosing results in infections, malignancy and direct toxicity to a number of organs. Pharmacokinetics heterogeneity makes initial dose determination difficult, as there is little correlation between dose and concentration in the blood.
Therapeutic drug monitoring(TDM) is available, but the pharmacokinetic-pharmacodynamic association, sometimes, is imperfect and does not help to achieve target blood concentrations either during the critical first days after transplantation or during the lifespan.
Therefore genetic polymorphisms in drug targets, metabolizing enzymes and drug efflux pumps have been identified as potential improvements for the development of new strategies to identify initial and maintain dose of Tacrolimus (FK-506)
Our aim is to plan pharmacogenetic studies in pediatric liver transplant patients to identify early the Tacrolimus dose, so to increase the Tacrolimus efficacy in term of patient and graft survival and/or decrease the most important adverse drug reactions.
Pharmacogenetics, Tacrolimus, FK-506, Liver transplantation, Therapeutic Drug Monitoring
PharmGKB - The Pharmacogenomics Knowledgebase